Press Release

FOR IMMEDIATE RELEASE

Rheologics Technologies, Inc. To Be Showcased in a Follow-Up Interview on ''The Heart Show with Dr. Vagnini''

March 31, 2006
Contact: Rheologics Technologies, Inc.
Teresa Shuler, 610-524-5427 or 800-969-2585

or

ISD, Inc.
Jody Janson, 585-232-5440

SINKING SPRING, Pa.--(BUSINESS WIRE)--March 31, 2006
Rheologics Technologies, Inc. (OTC:RTGI; "Rheologics", "the Company"), the leader in the study of blood viscosity and its relationship to vascular disease, is pleased to announce that Dr. Ralph Holsworth and President Daniel J. Cho will be interviewed this Sunday April 2nd at 4:00 pm EST in a follow-up interview on "The Heart Show with Dr. Vagnini" in New York City. The show will be broadcast on radio station WOR RADIO 710 AM in the New York metropolitan area and may be listened to over the world wide web under the "Special Weekend" link at www.wor710.com.

On the March 26, 2006 broadcast, Dr. Vagnini spoke with Rheologics' Director of Scientific Research Dr. Kenneth R. Kensey and Dan Cho about the company's signature device, the Rheolog(TM), which is the first clinical blood viscometry device of its kind. The Rheolog(TM) is a Scanning Capillary Tube Viscometer enabling clinicians and researchers to obtain a complete and accurate whole blood viscosity profile in real-time at the point of care or in the laboratory. Dr. Ralph Holsworth and Dan Cho will be following up last week's overview of the potential clinical and practical applications of the Rheolog(TM) with a discussion of a new therapeutic compound, called RheoGen(TM).

Dr. Holsworth, who serves on the Rheologics management team as Executive Vice President of Pharmaceuticals and is recognized as the leading authority in enzyme-related therapeutic compounds in the U.S., states: "Dr. Vagnini is one of a kind. He transformed his New York City medical practice from cardiovascular surgery to cardiovascular prevention and nutrition. I am looking forward to appearing on his program and discussing the significant developments that Rheologics has made in the field of vascular disease prevention and treatment."

Dan Cho, President of Rheologics, added, "Dr. Vagnini is much more than a charismatic media personality. He is a true physician -- genuinely interested in helping people beat vascular disease and improving the quality of their lives, and he is quickly becoming an expert on whole blood viscosity, which we believe is tied to the ultimate cause of heart disease."

About "The Heart Show with Dr. Vagnini"
"The Heart Show with Dr. Vagnini" utilizes a listener call-in format that discusses the most pressing issues regarding a variety of health topics from diabetes to heart disease and stroke. Along with hosting the radio show, Dr. Frederic Vagnini serves as the Medical Director of the Heart, Diabetes & Weight Loss Centers of New York in Manhattan and Westbury, Long Island and is a board-certified cardiovascular surgeon that has turned his focus to the prevention of heart and related diseases. He has been a frequent guest on local and national radio and television, with recent appearances on Dateline NBC in December 2005. He has authored and co-authored five books, including the New York Times bestseller, The Carbohydrate Addict's Healthy Heart Program, The Side Effect Bible, and his most recent release, Overcoming Metabolic Syndrome, which was written with Dr. Scott Isaacs, a board-certified endocrinologist in Atlanta, Georgia and Clinical Instructor of Medicine at Emory University School of Medicine. Dr. Vagnini also publishes a monthly newsletter, the "Cardiovascular Wellness Newsletter" which can be accessed through his website: www.vagnini.com.

About Rheologics, Inc.
Rheologics Technologies, Inc. is committed to developing and commercializing innovative medical products that significantly improve the diagnosis and treatment of human disease and that assist in the development of new drug compounds. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its proprietary innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding the following: the Company's beliefs about the benefits of its technology; the Company's expectations of its technology; the Company's beliefs about the performance capabilities of its technology; the Company's ability to commercially license its technology; the ability of the Company to hire employees sufficient to accelerate engineering and testing; and the Company's beliefs regarding its research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, our inability to achieve commercial acceptance of our technology, our inability to compete effectively in the marketplace, our inability to improve or implement effective systems, procedures and controls, the strength of our patent and pending patents and other intellectual property and those of our competitors, our inability to protect our intellectual property, our inability to attract, train and retain key personnel, and such other risks. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.